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SUMMARY
Background. In the case of an alternative psychosis (AP) or forced normalization (FN), the patient alter-
nates between periods of clinically manifest seizures and normal behavior, and other periods of seizure 
freedom or significant seizure reduction accompanied by psychosis or behavioral disturbances. In clinical 
practice and in the literature, the terms AP and FN are mostly used synonymously despite small differenc-
es. FN of the EEG is not only common to interictal mental disturbances but may also occur in the case of 
pre-ictal and postictal mental disturbances.
Aim. To update the 2007 review on “Alternative Psychoses of Epilepsy” in this journal with special consid-
eration of the new anticonvulsants.
Material and Methods. We conducted a literature research from 1987 (in this year a psychosis, triggered 
by the first “new “anticonvulsant vigabatrin in a patient with epilepsy was reported for the first time) up 
to September 2019.
Discussion. AP/FN are rare events; only 10% of epileptic psychosis are AP/FN. AP/FN respectively occur 
with both generalized and focal epilepsy; in recent years, patients with focal epilepsy predominate. AP/FN 
generally present with behavioral disturbances of acute or subacute onset associated with thought disor-
der, delusions, hallucinations, significant mood change, or anxiety with depersonalization and derealiza-
tion symptoms. The reports on EEG findings in patients with AP are inconsistent. In the case of FN, the EEG 
is by definition normal or substantially improved. The most prominent risk factor for the development of 
an AP/FN is the anticonvulsant medication. The following anticonvulsants have not been observed until 
now as triggers of an AP/FN in the literature reviewed by us: Acetazolamide and sulthiame (“old” anti-
convulsants) and the “new” anticonvulsants brivaracetam, eslicarbazepine, pregabalin, retigabine, rufina-
mide, stiripentol. The treatment is based on 3 strategies: Reduction or complete cessation of anticonvul-
sants, change of anticonvulsants and administration of antipsychotic drugs.
Conclusion. The risk of an AP/FN is probably different for the individual dugs. At the current level of expe-
rience, gabapentin, pregabalin, oxcarbazepine or eslicarbazepine can be the first alternative if an AP/FN 
was triggered by another anticonvulsant in a patient with focal epilepsy. In generalized epilepsy, especial-
ly in patients with absences, valproic acid remains the first alternative.
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BACKGROUND
In 2007, we published a review “Alternative psycho-
ses of epilepsy” in Epileptologia (Fröscher and Steinert, 
2007). In May 2019, Professor Jerzy Majkowski in his 
capacity of Editor-in-Chief, proposed an update of this 
review and we agreed to do so in mid-2020. Professor 
Majkowski always had a special interest in psychiatric 
disturbances in epilepsy, and he himself published on 
the subject of forced normalization (FN; Majkowski, 
2005). We are deeply moved that Professor Majkowski 
passed away two months later.
Since the 18th century the phenomenon of the alter-
nation of seizures and psychiatric disturbances has been 
recognised in some patients. This phenomenon was 
characterized as “forced normalization“ (of the EEG) 
by Landolt (1955). Landolt was an expert in epileptol-
ogy and electroencephalography (EEG) and focused 
more on the changes of the EEG than on the clinical 
presentation. Ten years later Tellenbach (1965), a psy-
chiatrist, coined the term “Alternativpsychose“, in Eng-
lish alternative/alternating psychosis.
According to the proposal of a commission of the 
ILAE “alternative psychosis“ has been defined as fol-
lows: The patient alternates between periods of clini-
cally manifest seizures and normal behavior, and oth-
er periods of seizure freedom accompanied by a behav-
ioral disturbance. The behavioral disturbance is often 
accompanied by paradoxical normalization of the EEG 
(forced normalization). The behavioral disturbance is 
polymorphic with paranoid and affective features. If 
EEG confirmation is available, the diagnosis should be 
qualified further as “with forced normalization of the 
EEG“. The diagnosis of AP should be made in the ab-
sence of the EEG (Krishnamoorthy et al., 2007).
Krishnamoorthy and Trimble (1999) proposed cri-
teria for FN including an established diagnosis of ep-
ilepsy and the presence of a behavioral disturbance of 
acute/subacute onset (characterized by one or more of 
the following: psychosis with thought disorder, delu-
sions, hallucinations; significant mood change, hypo-
mania/mania or depression; anxiety with depersonal-
ization, derealization; hysteria), with concomitant re-
duction of epileptic activity in the EEG, and/or com-
plete cessation of clinical seizures for at least 1 week. 
The expected EEG changes are very detailed (reduc-
tion in the total number of spikes counted in a 60-min. 
awake EEG recording by over 50% compared to a sim-
ilar recording performed during a normal state of be-
havior and others. However, other EEG findings than 
spikes (such as focal slow activity) are not discussed.
Other names for the alternation between periods of 
clinically manifest seizures and normal behavior are 
the following: para-ictal psychosis (Agrawal and Mula 
2019), paradoxical normalization (Wolf, 1991) and Lan-
dolt’s phenomenon (Mula, 2010). Also, in 2019, there 
are no generally agreed diagnostic criteria for AP and 
FN (Agrawal and Mula, 2019). The terms AP and FN 
are not used in the ICD-10 (International Statistical 
Classification of Diseases and Related Health Prob-
lems) and DSM-5 (Diagnostic and Statistical Manual 
of Mental Disorders). Unfortunately, in both classifi-
cation systems AP and FN are not distinguished from 
non-alternating psychoses and behavioral disturbanc-
es in patients with epilepsy.
The terms AP and FN are frequently used synony-
mously, although this is inaccurate.
FN always comprises mental disturbances (Krish-
namoorthy and Trimble, 1999; Landolt 1955), however, 
a „forced normalization “of the EEG is not only com-
mon to interictal mental disturbances but may also oc-
cur in the case of pre-ictal and postictal mental distur-
bances (Fröscher and Steinert, 2019). An alternative psy-
chosis (or other alternative mental disturbances), how-
ever, may occur without normalization of the EEG or 
even with a deterioration of the EEG. The drawback of 
the term “alternative psychosis“ is the restriction to psy-
chotic phenomena, not covering other mental distur-
bances such as mood disorders or anxiety, which may 
appear alternatively. However, the somewhat vague 
terms AP and FN have become integral parts of med-
ical nomenclature. In the international literature, the 
term FN seems to be used more often than AP.
When we evaluated the case reports on AP and FN 
published in the years 1987–2017 a joint evaluation 
was possible without difficulties (we only had to ex-
clude 3 cases of FN that were associated with postictal 
psychoses (Fröscher and Steinert, 2019). The remain-
ing 66 patients, all of whom had been published as AP 
or FN, had “alternative “mental disturbances (mostly 
psychoses). The EEG-findings were reported only in 43 
of the 66 patients. In 40 of these 43 patients, the clini-
cal syndrome corresponded to both the AP and the FN 
concept; only in 3 patients the EEG findings remained 
unchanged during the period of mental disturbanc-
es compared to the period prior to these disturbances.
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For this update we conducted a literature research from 
1987 (in this year a psychosis, triggered by the new 
anticonvulsant vigabatrin in a patient with epilepsy 
was reported for the first time) up to September 2019 
with the terms “alternative psychosis of epilepsy (AP), 
forced/paradoxical/spurious normalization, Landolt’s 
phenomenon“. The following databases were searched: 
Medline (inclusive Epub ahead of Print, In-Process & 
Other Non-Indexed Citations, Daily Medline), Embase, 
Psycinfo und Psyndex.
RESULTS AND DISCUSSUON
Clinical syndrome
Epidemiology
As already stated in 2007 (Fröscher and Steinert, 2007), 
AP and FN were rarely diagnosed phenomena. The hope 
that they would become even rarer with the declining 
prescription of “old “anticonvulsants such as pheno-
barbital and phenytoin has not been realized. In ad-
dition to the cases provoked by anticonvulsants, there 
are now cases provoked by epilepsy surgery or vagus 
nerve stimulation.
In the literature the frequency of psychotic episodes 
of any type in patients with epilepsy is estimated at 
0.5–10% (Fröscher and Steinert, 2019). According to 
Schmitz (2012), only 10% of epileptic psychoses are al-
ternative psychoses, according to Mula (2010) the prev-
alence of FN is estimated at approximately 1% of pa-
tients with intractable epilepsy.
Type of epilepsy
AP and FN, respectively, occur with both generalized 
and focal epilepsy. In earlier studies on psychoses with 
epilepsy there was a significant correlation between gen-
eralized idiopathic epilepsies and psychoses with FN as 
a consequence of the high risk associated with a treat-
ment with ethosuximide (Wolf, 1991). In recent years, 
more patients with a focal, particularly a temporal lobe 
focus, have been observed with the development of alter-
native psychiatric disturbances (Calle-López et al., 2019; 
Fröscher and Steinert, 2019; Krishnamoorthy and Trim-
ble, 1999). In the review of Fröscher and Steinert (2019), 
47 out of 60 patients had a focal epilepsy (41 focal, 6 fo-
cal and generalized). The most frequent type of seizures 
were complex focal seizures. AP/FN is rare in patients 
with mainly generalized tonic-clonic seizures and in 
extra-temporal lobe epilepsy (Agrawal and Mula, 2019).
Age and gender
Alternative psychoses may occur in every period of life. 
Even in children aged 2 or 3 years, psychiatric symp-
toms have been associated with abrupt seizure cessa-
tion and normalization of the EEG (Amir and Gross-
Tsur, 1994). In older age AP/FN are rarely observed 
(Fröscher and Steinert, 2019).
An association of AP/FN with gender was not con-
firmed in the older literature (Schmitz and Trimble, 
2005); however, two recent reviews report a higher inci-
dence in women (Calle-López et al., 2019; Fröscher and 
Steinert, 2019). In the cases reported by Fröscher and 
Steinert (2019), women were affected more than twice 
as often as men; as a cause of this gender discrepancy 
a higher dose of anticonvulsants on average per body 
weight has been considered.
Clinical presentation
With regard to the clinical presentation, no new find-
ings have emerged in recent years. The clinical presenta-
tion is nonspecific and there are no generally agreed di-
agnostic criteria for AP/FN (Agrawal and Mula, 2019). 
AP/FN generally presents with behavioral disturbanc-
es of acute or subacute onset, associated with thought 
disorder, delusions, hallucinations, significant mood 
change (hypomania or depression), and anxiety with 
depersonalization or derealization symptoms. It is as-
sociated with a reduction in the total number of spikes 
and/or clinical report of complete cessation of seizures 
for at least one week (Agrawal and Mula, 2019; Krish-
namoorthy and Trimble, 1999). In our review of 66 pa-
tients with AP/FN, in 39 of these patients the mental 
symptoms were described as “psychosis “; 19 of these 
patients had hallucinations (auditory, visual, olfactory, 
tactile), 15 patients had delusional ideas. The remain-
ing 27 patients had the following symptoms as alterna-
tive phenomena (with decreasing frequency): aggres-
siveness, irritability, depression, “behavioral distur-
bances“, sleep disturbances (in most cases insomnia), 
agitation/restlesness, fits of rage, anxiety, pseudo-sei-
zures (Fröscher and Steinert, 2019).
Calle-López et al. (2019) analyzed 77 cases of FN. 
Patients presented psychosis (86.4%), mood disorders 
(25.8%), and dissociation (4.5%) as the main manifesta-
tions. In the psychosis group, persecutory (52.6%) and 
reference (47.3%) delusions were frequent. In gener-
al, delusions were more common in patients with tem-
poral lobe epilepsy in comparison to patients with ex-
tratemporal and generalized epilepsies.
Forced normalization and alternative psychosis
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The psychoses usually occur in a state of clear con-
sciousness. While some authors suggested that psychot-
ic episodes in patients with epilepsy are indistinguisha-
ble from those of “classic“ schizophrenia, other studies 
observed a minor severity and a better response to ther-
apy in alternative psychoses (Kanner, 2000; Klosterköt-
ter and Penin, 1989; Schmitz and Trimble, 2005).
EEG findings
The reports on EEG findings in patients with AP/FN 
are inconsistent. For example, Köhler (1975) rarely 
found a normal or normalized EEG during a AP/FN. 
Krishnamoorthy and Trimble (1999), however, in cas-
es of FN proposed the following ÊEG findings as “pri-
mary criteria“: Reduction in the total number of spikes 
counted in a 60 minute awake EEG recording with 
a 16-channel machine, using standard 10-20 electrode 
placement, by over 50% compared to a similar record-
ing performed during a normal state of behavior.
The review of Calle-López et al. (2019) only includ-
ed publications which fulfilled these criteria; data on 
the variety of EEG findings in cases of alternative men-
tal disturbances are therefore not presented. Case re-
ports on an AP/FN communicated in the literature of-
ten do not take into account the stringent criteria of Kr-
ishnamoorthy and Trimble (1999) or only cite incom-
plete EEG findings. In our own review (Fröscher and 
Steinert, 2019) we included cases of AP even with miss-
ing or incomplete EEG findings as completely as pos-
sible, in order to detect triggering anticonvulsants. In 
most cases of AP where EEG findings had been report-
ed, an improvement or normalization of these findings 
had been observed.
Clinical course
Usually AP/FN evolve within days, months or even 
years after cessation or marked reduction of seizures. 
The duration of an AP/FN amounts to some days up 
to many months (Fröscher and Steinert, 2007). In the 
study of Calle-López et al. (2019), the mean duration 
of FN episodes was 111 ± 384 (1–2880) days; FN lasted 
more than 3 weeks in 42% of patients. In the study of 
Fröscher and Steinert (2019), the mean duration of an 
AP/FN episode was one month (3 days – several years, 
n  = 35 patients); obviously the duration is very differ-
ent. An AP/FN episode may be terminated spontane-
ously, by spontaneous seizures, by seizures induced by 
reduction of the anticonvulsant medication or by an-
tipsychotic drugs (see below, treatment).
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The development of a chronic psychotic state is con-
sidered to be a rare event. There are, however, some pa-
tients who alternate repeatedly between periods with 
seizures and seizure-free periods with mental deterio-
ration (Fröscher and Steinert, 2007). In the case series 
reported by Fröscher and Steinert (2019), at least 12 out 
of 66 patients had repeated episodes of an AP/FN. In the 
study of Calle-López et al. (2019), psychiatric symptoms 
could be controlled completely in 65% of the cases; 27% 
of the patients persisted with few mild psychiatric symp-
toms and 6% of the patients continued showing severe 
behavior disturbances despite treatment. The treatment 
that had induced FN made a difference for the clinical 
course. The majority (87.5%) of FN cases triggered by 
anticonvulsants presented complete resolution of the 
symptoms with the drug withdrawn, in comparison to 
the cases triggered by vagus nerve stimulation and sur-
gery. Fifty percent of FN cases triggered by vagus nerve 
stimulation and 28.5% of FN cases triggered by surgery 
had a complete clinical resolution. In the surgical cases 
the trigger was irreversible and antipsychotic drugs were 
not completely effective. Among the vagus nerve stim-
ulation-cases there was one successful case, which im-
proved after a change in the pulse intensity of stimulation.
In our group of patients with an anticonvulsant-trig-
gered AP/FN (n = 47; Fröscher and Steinert, 2019), the 
mean of the interval between onset of epilepsy and 
the first episode of AP/FN was 15 years (range: sever-
al weeks up to 43 years).
Differential diagnosis
In seizure-free patients with a psychosis, an iatrogen-
ic effect of anticonvulsant drugs has to be considered. 
The clinical differentiation between AP/FN and a tox-
ic reaction to anticonvulsants can be difficult if a sei-
zure-free state followed the introduction of an anticon-
vulsant (Kanner and Rivas-Grajales, 2016). The proba-
bility of an AP/FN is supported if the EEG course shows 
a “forced” normalization. An improvement of psychi-
atric disturbances in these patients by spontaneous sei-
zures also supports the diagnosis of an AP/FN (Mar-
chetti et al., 2003). AP/FN becomes a less likely explana-
tion if the symptoms resolve when the patient is transi-
tioned to an alternative drug and remains seizure-free 
with a normal EEG (Bui et al., 2014).
Risk factors, especially anticonvulsants
Risk factors for the development of drug-induced 
AP/FN include a long-lasting focal epilepsy with phar-
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macoresistance, a history of status epilepticus, psy-
chosis, psychiatric disturbances, mental retardation 
and unfavourable psychosocial factors (Fröscher and 
Steinert, 2001; Majkowski, 2005). FN/AP seem to be 
more frequent in patients with temporal lobe epilepsy 
(Calle-López et al., 2019). The most prominent risk fac-
tor is probably the anticonvulsant medication. Several 
authors report that AP/FN has been described with all 
anticonvulsants, suggesting that this is not a drug-spe-
cific phenomenon but instead linked to the neurobio-
logical mechanism underlying seizure control. In fact, 
as highlighted above, cases of an AP/FN have been de-
scribed with vagus nerve stimulation and after epilep-
sy surgery (Agrawal and Mula, 2019).
During the period when only the older anticonvul-
sants were available, and the succinimides were the 
treatment of choice for the treatment of absence sei-
zures, they were most often associated with the devel-
opment of an AP/FN. The new anticonvulsants do not 
seem to bear an equal risk.
AP/FN gained renewed attention when, since 1990, 
a number of cases had been observed that had been 
triggered by the new anticonvulsant vigabatrin. Most 
other new anticonvulsants have also been reported to 
trigger an AP/FN in the following years.
In the period from 1987 to 2017, we reported 66 pub-
lished AP/FN cases (Fröscher and Steinert, 2019). On-
ly 15 out of 66 patients were treated with monotherapy, 
reducing the accountability to single components. The 
most commonly triggering anticonvulsants were (with 
decreasing frequency): vigabatrin, levetiracetam, etho-
suximide, carbamazepine, valproic acid.
Once to three times the following anticonvul-
sants were described as triggers: lamotrigine, pheny-
toin, topiramate, zonisamide, ACTH (corticotropin), 
clonazepam, lacosamide, methsuximide, phenobar-
bital, primidone, midazolam, perampanel, sirolimus 
(reduces seizure frequency, Wiemer-Kruel et al., 2009). 
Not yet considered in our review was the report of Kite-
va-Trenchevska (2018) on 4 cases of an AP/FN triggered 
by levetiracetam.
In 4 retrospective studies, another 176 alternative 
episodes were reported, but some details are missing. 
In these studies, the most common triggering anticon-
vulsants were (with decreasing frequency): vigabatrin, 
carbamazepine, phenytoin, phenobarbital, topiramate, 
valproic acid, zonisamide, lamotrigine. Gabapentin and 
oxcarbazepine are mentioned twice, tiagabine once as 
triggering anticonvulsants.
In the study of Calle-López et al. (2019), the trigger-
ing anticonvulsants were (with decreasing frequen-
cy): Levetiracetam, vigabatrin, carbamazepine, lam-
otrigine, ethosuximide, lacosamide, valproic acid and 
once topiramate and phenytoin. The cases reported 
in this study partly correspond to the cases of our re-
view. Other than in our review (Fröscher and Steinert, 
2019), Calle-López et al. (2019) included cases report-
ed since 1953 (the year of the first publication on FN 
by Landolt (1953); however, only papers were includ-
ed that fulfilled the FN criteria established much lat-
er by Krishnamoorthy and Trimble (1999). As a result, 
pre-1999 publications are probably under-represented. 
This may explain why phenytoin-triggered episodes 
are rare and phenobarbital/primidone-triggered epi-
sodes are absent.
In various reviews, the following additional anti-
convulsants are reported as triggers of an AP/FN: Bro-
mides, clorazepate, felbamate, mephenytoin, phenu-
rone (Fröscher and Steinert, 2019). Recently, an episode 
of FN likely triggered by cannabidiol was reported for 
the first time (Sands et al., 2019). To date the following 
anticonvulsants have not been reported as triggers of 
an AP/FN in the literature reviewed by us: acetazola-
mide and sulthiame (“old” anticonvulsants) and the 
“new” anticonvulsants brivaracetam, eslicarbazepine, 
pregabalin, retigabine, rufinamide and stiripentol. The 
frequency of case reports for individual drugs is rather 
limited in predicting the extent of the risk of an AP/FN 
by specific drugs. Of course, the frequency of reports 
depends on the frequency of prescriptions and the time 
a drug was licensed for clinical use. Noteworthy, how-
ever, is the number of communications relating to VGB 
that were published within a few years of introduction. 
The frequent mention of levetiracetam is at least par-
tially related to the frequent prescription of this wide-
ly used anticonvulsant. In 2013, levetiracetam was the 
most widely prescribed anticonvulsant in Germany, fol-
lowed by lamotrigine (Willems et al., 2018). At the cur-
rent level of experience, gabapentin, pregabalin, oxcar-
bazepine or eslicarbazepine can be considered the first 
alternative anticonvulsant if an AP/FN was triggered 
by another anticonvulsant in a patient with focal epi-
lepsy (Fröscher and Steinert, 2019). For brivaracetam, 
lacosamide and perampanel the short time of clinical 
experience does not allow a general recommendation. 
In generalized epilepsy, especially in patients with ab-
sences, valproic acid remains the first alternative anti-
convulsant of choice.
12
Treatment
The treatment of an AP/FN has changed from previous 
recommendations only insofar as more anticonvulsants 
are available as an alternative. Three strategies, which 
do not exclude each other, may be used:
1.  Reduction or complete cessation of anticonvulsants.
2. Change of anticonvulsants: if strategy 1 does not 
work and the desirable balance cannot be found, 
the anticonvulsant has to be changed. In some pa-
tients the change of the anticonvulsant, for exam-
ple from ethosuximide to valproic acid (Wolf et al., 
1984), may be sufficient. In this case there is a sub-
stance-specific effect, an effect that Kanemoto et al. 
(2001) also report. These authors describe patients, 
who became psychotic after seizure control with 
zonisamide or phenytoin, but not after seizure con-
trol by other anticonvulsants. In other cases, it is not 
the substance-specific effect that is decisive, but the 
fact of seizure suppression, regardless of which ther-
apeutic measure is in use. In such patients AP/FN 
was not only triggered by seizure suppression by an-
ticonvulsants but also by vagus nerve stimulation 
(Anzellotti et al., 2014) or epilepsy surgery (Kane-
moto et al., 2012).
3. Antipsychotic drugs: if the reduction or change of 
anticonvulsants is not effective, antipsychotics and 
in a few cases, antidepressants are recommended. 
Antipsychotic drug use does not predict complete 
remission of psychiatric symptoms in comparison 
with the withdrawal of anticonvulsants (Calle-López 
et al., 2019; Fröscher and Steinert, 2019). The deve-
lopment of a chronic psychotic state is considered to 
be a rare event. There are, however, some patients 
who alternate repeatedly between periods with sei-
zures and seizure free periods with mental deterio-
ration (Fröscher and Steinert, 2019).
Limitations
The major limitation of this approach is that the collect-
ed case reports do not represent a clinical sample and 
might not be representative for the incidence of AP/FN 
cases under naturalistic treatment conditions. A publi-
cation bias is possible in several respects. Case reports 
are published by physicians who are interested in re-
search and those might be the same physicians who are 
interested in collecting experiences with newer anticon-
vulsants. In addition, new observations, such as obser-
vation of AP/FN under treatment with recently intro-
duced anticonvulsants, will be submitted and accept-
ed for publication with higher probability than well-
known phenomena. For these reasons, the incidence 
of AP/FN under newer anticonvulsants in relation to 
the older ones might be overestimated in this review.
CONCLUSION
Phenomena of AP and FN in patients with epilepsy are 
rare events. However, knowledge of these syndromes is 
important to be able to initiate correct treatment quick-
ly. AP/FN are triggered by suppression of seizures both 
by anticonvulsants as well as by other treatment meas-
ures such as epilepsy surgery and vagus nerve stimula-
tion. The risk of an AP/FN is probably different for the 
different dugs. At the present level of experience, gabap-
entin, pregabalin, oxcarbazepine or eslicarbazepine can 
be considered the first alternative choice if an AP/FN is 
triggered by another anticonvulsant in a patient with 
focal epilepsy. For brivaracetam, lacosamide and per-
ampanel the limited experience of their clinical use 
does not allow a general recommendation to be made. 
In generalized epilepsy, especially in patients with ab-
sences, valproic acid remains the first alternative choice.
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